Picture of Brainstorm Cell Therapeutics logo

BCLI — Brainstorm Cell Therapeutics News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapMomentum Trap

Brainstorm Cell Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary

* Brainstorm Cell Therapeutics Inc  BCLI.OQ  reported a
quarterly
adjusted loss of 51 cents​​ per share for the quarter ended
September 30, lower than the same quarter last year, when the
company reported EPS of -45 cents.  The mean expectation of
two analysts for the quarter was for a loss of 57 cents per
share. Wall Street expected results to range from -70 cents
to -45 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Brainstorm Cell Therapeutics Inc's reported EPS for the
quarter
was a loss of 51 cents​.
    * The company reported a quarterly loss of $2.71 million.
    * Brainstorm Cell Therapeutics Inc shares had fallen
by 67.3% this
quarter and lost 72.4% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 9.5%
in the last three months.​ 
    * In the last 30 days, one analyst negatively revised an
earnings
estimate

RECOMMENDATIONS
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 2 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is  "buy."

Wall Street's median 12-month price target for Brainstorm Cell
Therapeutics Inc is $22.51 
This summary was machine generated from LSEG data November 15 at
02:10 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2024      -0.57          -0.51          Beat
 Jun. 30 2024      -0.52          -0.60          Missed
 Mar. 31 2024                     -0.75          
                                  -0.60

Recent news on Brainstorm Cell Therapeutics

See all news